Data from a great Australian registry of nearly 250,000 people with a 5-year follow-up, presented at the European Society of Cardiology (ESC) Congress 2019 in Paris and simultaneously published in J Am Coll Cardiol, suggest that mortality due to severe aortic stenosis is similar to that due to moderate aortic stenosis. These data warn us<a href="https://solaci.org/en/2019/09/10/esc-2019-how-benign-is-moderate-aortic-stenosis/" title="Read more" >...</a>
Chronic kidney disease, even in moderate or severe stages before dialysis, is associated with an increased risk of aortic stenosis according to this work recently published in J Am Coll Cardiol. Both share several risk factors, something that complicates the identification of the association between these diseases due to multiple confounding variables. The study<a href="https://solaci.org/en/2019/04/16/kidney-insufficiency-and-the-risk-of-developing-aortic-stenosis-in-the-future/" title="Read more" >...</a>
For the first time, this long term observational study on a large cohort of contemporary patients with aortic stenosis (AS), has shown syncope is an underestimated threat, associated with worse prognosis after surgical aortic valve replacement (SAVR). It is interesting to note that other symptoms or early signs of AS that will normally indicate SAVR<a href="https://solaci.org/en/2019/02/11/un-underestimated-symptom-of-aortic-stenosis/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Asymptomatic severe aortic stenosis with preserved ventricular function is challenging. At present, it remains unclear whether we should operate or not and, according to some recent reports, neither do we know what patients will benefit from surgery. The study looked at 1678 patients with asymptomatic or minimally asymptomatic severe aortic<a href="https://solaci.org/en/2019/02/06/how-long-should-we-wait-with-asymptomatic-aortic-stenosis-and-preserved-lvef/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Aortic stenosis happens in 2.8% of patients over 75, and is even more frequent in dialysis patients. However, it remains unclear whether kidney dysfunction increases the risk of aortic stenosis. The present study looked at 1,121,875 patients from the SCREAM project (Stockholm CREAtinine Measurements). Mean age was 50, and<a href="https://solaci.org/en/2019/01/29/are-aortic-stenosis-and-kidney-dysfunction-associated/" title="Read more" >...</a>
Once a big void that prevented us from effectively assessing functional compromise, intermediate aortic stenosis has made us treat many lesions “just in case”, to save us what would be a complicated procedure, had a valve been placed. Auspiciously, some light has been shed by several, most welcome, studies simultaneously published in J Am Coll<a href="https://solaci.org/en/2018/10/31/ifr-assessment-of-intermediate-aortic-stenosis-lesions-consolidates/" title="Read more" >...</a>
This systematic analysis measured intracoronary pressure in different phases of the cardiac cycle and flow velocity in patients with severe aortic stenosis and coronary artery disease, who were scheduled for transcatheter aortic valve replacement (TAVR). The aim was to determine the impact of aortic stenosis on: 1) flow, at different phases; 2) hyperemic coronary flow;<a href="https://solaci.org/en/2018/10/30/what-should-we-use-for-the-functional-assessment-of-coronary-lesions-in-severe-aortic-stenosis/" title="Read more" >...</a>
Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress. See the presentation by Dr. Lee Benson, entitled “Neonatal Aortic Stenosis Is a Surgical Disease… Really, in 2018?”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
Courtesy of Dr. Carlos Fava. Transcatheter aortic valve replacement (TAVR) has been proven to reduce mortality and improve the quality of life of patients with pure severe aortic stenosis (PAS). However, there is a significant number of patients who experience mixed aortic stenosis associated with moderate/severe aortic regurgitation (MAS). These subjects were excluded from the PARTNER<a href="https://solaci.org/en/2017/12/12/tavr-in-patients-with-pure-vs-mixed-aortic-stenosis-benefits-and-evolution/" title="Read more" >...</a>
Frailty is the patient’s diminished capacity to recover after pathological or iatrogenic processes. It has a fundamental role when considering valve replacement, be it surgical (SAVR) or transcatheter (TAVR). This was clearly observed in the PARTNER I and Core-Valve Pivotal trials, which showed that despite a 95% technical success, 2 in 5 patients showed poor quality<a href="https://solaci.org/en/2017/08/16/how-to-standardize-frailty-in-aortic-stenosis-patients/" title="Read more" >...</a>